Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Business Wire 2 days ago

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

Business Wire April 12, 2024

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 27, 2024

Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

Business Wire March 4, 2024

Revance Announces Proposed Public Offering of Common Stock

Business Wire March 4, 2024

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

Business Wire February 28, 2024

Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

Business Wire February 21, 2024

Revance to Participate in Upcoming Investor Conferences

Business Wire February 21, 2024

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

Business Wire February 2, 2024

Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference

Business Wire February 1, 2024

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

Business Wire January 8, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

Newsfile November 9, 2023

Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

Business Wire November 8, 2023

Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics

Business Wire November 8, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

Accesswire November 7, 2023

Revance to Participate in Upcoming Investor Conferences

Business Wire November 6, 2023

Revance Therapeutics, Inc. (RVNC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 5, 2023

Revance Therapeutics, Inc. (RVNC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 4, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

PR Newswire November 3, 2023

Revance Therapeutics, Inc. (RVNC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire November 3, 2023